Universal Biosensors (ASX:UBI) share price is lifting today. Here's why

The Universal Biosensors share price is rising today after the company signed a Canadian distribution agreement for its wine testing platform.

| More on:

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

rising ASX share price represented by cork popping out of wine bottle

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Universal Biosensors, Inc (ASX: UBI) share price is rising today after the company signed a Canadian distribution agreement for its wine testing platform.

At the time of writing, the Universal Biosensors share price is up 1.96% trading at 52 cents.

The deal represents an interesting step towards diversified commercialisation for Universal Biosensors. The company is primarily a medical diagnostics company, focused on the research, development, and manufacture of in-vitro diagnostic test devices for consumer and professional point-of-care use.

The company produces technology that tests blood glucose levels, which has enabled it to expand into the viticulture market through its new wine testing platform, Sentia.

Sentia can accurately test the levels of glucose, fructose, malic acid and other monosaccharide carbohydrates in wine, which is already proving appealing for international winemakers.

Universal Biosensors meets Vine to Vintages

Universal Biosensors announced today it has entered into a nonexclusive distribution agreement with Canadian company Vines to Vintages Inc for the distribution of its wine testing platform device.

The agreement is for a three-year term and contains standard renewal and termination options available to both parties. The Canadian distribution agreement arrives two months after Universal Biosensors signed a US distribution deal with Enartis, with more than 7,000 potential customers.

The company outlined to shareholders in its 'Future of UBI' report in February that it planned to "move away from defining ourselves as an R&D company with long lead times and expensive research programs". Since then, the Universal Biosensors share price has risen by more than 10 cents.

What did management say?

Universal Biosensors CEO John Sharman welcomed the deal, saying:

The launch of Sentia into Canada is another positive step in the commercialisation of Sentia globally. Vines to Vintages is well represented in all of Canada's wine regions and has access to 700 wineries.

The deal includes an initial commitment to purchase Sentia devices and strips which will be delivered over the course of the next few weeks.

Mr Sharman said the possibility of Sentia's future testing capability for glucose, fructose, malic acid and others would add "significant value" to the winemaking industry.

We are negotiating terms with a number of key industry players around the world and look forward to reporting additional distribution partnerships in due course.

Universal Biosensors share price snapshot

The Universal Biosensors share price has increased more than 245% in the past year. It's up 28% this month, 19% this calendar year and 250% against the broader healthcare sector, although healthcare is hardly a sector Universal Biosensors is limited to anymore.

Motley Fool contributor Lucas Radbourne-Pugh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »